Evommune's stock dropped about 38% after its lead drug EVO756 missed the primary endpoint in a Phase 2b trial for chronic spontaneous urticaria, wiping out millions in shareholder value. This failure removes the nearest regulatory milestone for the drug, though Evommune plans to continue developing EVO756 for other conditions like atopic dermatitis and migraine. Investors who suffered losses are being encouraged to seek legal advice regarding potential recovery options.
Nasdaq announced that Pitanium Limited's securities will be delisted from the Nasdaq Stock Market on July 16, 2026, unless the company appeals the decision. Trading of Pitanium shares has been halted since October 18, 2025, following a suspension by ...
Nasdaq has notified Platinum Analytics Cayman Limited that its securities will be delisted from the Nasdaq Stock Market on July 16, 2026, unless the company appeals. Trading in the company's shares has been halted since October 18, 2025, following a ...
AIsa, a platform enabling AI agents to transact for digital resources, raised $6.5 million in a seed round led by Alibaba and Tribe Capital. The funding will expand engineering, scale payment infrastructure, and enhance stablecoin settlements. AIsa a...
Holzer & Holzer, LLC announced deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against BitGo Holdings, Erasca, and First Solar. These lawsuits allege that the companies made misleading statements or failed t...
BMO has committed $500,000 over five years to the National Music Centre's Music Therapy Initiative, with matching funds from The Jim Pattison Foundation. This investment will expand music therapy programs in hospitals and community health settings ac...
